Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Aug 3, 2011

Merck & Co. Teams Up with India’s Serum Institute to Develop PCV Vaccine for Developing World

Merck & Co. Teams Up with India’s Serum Institute to Develop PCV Vaccine for Developing World

Arrangement will see Merck and Serum divide marketing rights for the pneumococcal conjugate vaccine. [© Thomas Brugger - Fotolia.com]

  • Merck & Co. and Serum Institute of India will develop and commercialize a pneumococcal conjugate vaccine (PCV) for use in developing countries. The companies will form a product advisory committee to oversee activities required to develop and seek approval for PCV and pursue World Health Organization (WHO) prequalification.

    Under terms of their collaboration agreement, Merck, through an affiliate, will receive specific rights to market PCV “in certain designated territories,” and Serum will receive specific rights in others. Both companies will contribute to the development and manufacture of PCV.

    "Working side by side with Serum gives us the best chance of developing and bringing a product to the market that will help to protect more babies and children," says Julie L. Gerberding, president, Merck Vaccines. "Expanding vaccine access to emerging and developing markets is a top priority, and we feel strongly that this collaboration will be a giant step toward impacting the devastation of pneumococcal disease."

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »